Effect of Indomethacin Treatment in Full-term Infants with Symptomatic Patent Ductus Arteriosus.
10.14734/kjp.2013.24.4.237
- Author:
Han Kyul KIM
1
;
In Su CHOI
;
Hwa Jin CHO
;
Eun Song SONG
;
Young Kuk CHO
;
Young Earl CHOI
;
Young Youn CHOI
;
Jae Sook MA
Author Information
1. Department of Pediatrics, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea. cardiol@jnu.ac.kr
- Publication Type:Original Article
- Keywords:
Indomethacin;
Patent ductus arteriosus;
Full-term infants
- MeSH:
Birth Weight;
Ductus Arteriosus, Patent*;
Gestational Age;
Humans;
Indomethacin*;
Infant*;
Infant, Newborn;
Infant, Premature;
Jeollanam-do;
Ligation;
Retrospective Studies
- From:Korean Journal of Perinatology
2013;24(4):237-243
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Indomethacin has been reported as the prophylaxis and initial treatment of preterm infants with patent ductus arteriosus (PDA). However, there was controversy over indomethacin treatment in full-term infants with symptomatic PDA. Therefore, we evaluate the effect of indomethacin as a treatment of full-term infants with symptomatic PDA. METHODS: A retrospective study was performed to evaluate the effectiveness of indomethacin in full-term infants who had birth weight > or =2,500 g and a gestational age > or =37 weeks with symptomatic PDA at Chonnam National University Hospital between January 2007 and December 2009. According to responsiveness of indomethacin, we classified them into three groups: 1) complete responder which were completely closed after indomethacin treatment, 2) partial responder which were incompletely closed but symptoms were improved, 3) non responder which were conducted surgical ligation because did not respond. RESULTS: Among the total 29 full-term infants treated with indomethacin, 13 (44.8%) were complete responder, 8 (27.6%) were partial responder, and 8 (27.6%) were non responder. There were no significant differences in birth weight, narrow diameter of PDA, and dose of indomethacin between three groups. However, the age at initiation of treatment using indomethacin of complete (4.8+/-4.5 days, P=0.03) and partial responder (6.3+/-2.0 days, P=0.04) were earlier than those of non responder (13.8+/-8.1 days). CONCLUSION: Indomethacin can expect an effective treatment of PDA in full-term infants prior to surgical ligation.
